产品说明书
Bimatoprost
 |
同义名 : | AGN 192024;17-phenyl trinor Prostaglandin F2α ethyl amide;Bimatoprostum;Latisse;Lumigan;17-phenyl trinor PGF2α ethyl amide;15(S)-Bimatoprost |
| CAS号 : | 155206-00-1 | |
| 货号 : | A147258 | |
| 分子式 : | C25H37NO4 | |
| 纯度 : | 98% | |
| 分子量 : | 415.566 | |
| MDL号 : | MFCD03411999 | |
| 存储条件： |
粉末 Sealed in dry,Store in freezer, under -20°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(252.67 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Bimatoprost, a synthetic prostamide F2α analog originally approved for the treatment of ocular hypertension and open-angle glaucoma, is now FDA approved as a 0.03%, solution to be applied once daily to increase eyelashes growth[3]. In March 2020, bimatoprost implant received its first approval, in the USA, for use to reduce intraocular pressure (IOP) in patient with open angle glaucoma or ocular hypertension[4]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.41mL 0.48mL 0.24mL |
12.03mL 2.41mL 1.20mL |
24.06mL 4.81mL 2.41mL |
| 参考文献 |
|---|